Table 2.
Results of Multivariate Analyses of ER-α36 Positive Versus ER-α36 Negative for DFS and DSS in Four Subgroups in Cohort 1
| Group | No.* | DFS |
DSS |
||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| ER-α66 positive/TAM+ | 307 | 1.92 | 1.17 to 3.14 | .009 | 2.48 | 1.40 to 4.40 | .002 |
| ER-α66 positive/TAM− | 129 | 0.84 | 0.38 to 1.85 | .67 | 0.79 | 0.34 to 1.83 | .58 |
| ER-α66 negative/TAM+ | 73 | 1.55 | 0.62 to 3.85 | .35 | 1.29 | 0.37 to 4.51 | .69 |
| ER-α66 negative/TAM− | 149 | 0.95 | 0.53 to 1.68 | .86 | 0.52 | 0.25 to 1.05 | .07 |
Abbreviations: ER-α36, estrogen receptor-α 36; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio; ER-α66, estrogen receptor-α 66; TAM+, chemotherapy plus tamoxifen or tamoxifen alone; TAM−, chemotherapy alone without tamoxifen treatment.
*
Twenty-nine ER-α66–positive patients and 15 ER-α66–negative patients in cohort 1 either did not receive adjuvant therapy or the adjuvant therapy information was not available, and the ER-α66 status is unknown in eight patients in cohort 1.